Postgraduate Program in Pneumological Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Postgraduate Program in Endocrinology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Respir Care. 2020 Aug;65(8):1189-1201. doi: 10.4187/respcare.07098. Epub 2020 Mar 24.
The benefits of inspiratory muscle training (IMT) for patients with COPD are documented in the literature, but its isolated effect or association with other interventions, the best training methods, and what type of patient benefits the most are not clear. We sought to assess the effects of IMT on respiratory muscle strength, pulmonary function, dyspnea, functional capacity, and quality of life for subjects with COPD, considering IMT isolated or association with other interventions, presence of inspiratory muscle weakness, training load, and intervention time.
We searched the MEDLINE, EMBASE, PEDro, Cochrane CENTRAL, and LILACS databases in June 2018. We also performed a manual search of references in the studies found in the database search and included in this analysis. We included randomized controlled trials that investigated the above-mentioned outcomes and assessed IMT, either isolated or associated with other interventions, in comparison with a control group, placebo, or other interventions, in subjects with COPD. We used the GRADE approach to evaluate the quality of the evidence.
Of 1,230 search results, 48 were included ( = 1,996 subjects). Isolated IMT increased P (10.64 cm HO, 95% CI 7.61-13.66), distance walked in 6-min-walk test (34.28 m; 95% CI 29.43-39.14), and FEV (0.08, 95% CI 0.02-0.13). However, there was no improvement in dyspnea and quality of life. The presence of inspiratory muscle weakness did not change the results; higher loads (60-80% of P) promoted a greater improvement in these outcomes, and a shorter intervention time (4 weeks) improved P, but longer intervention times (6-8 weeks) are required to improve functional capacity. IMT associated with other interventions only showed an increase in P (8.44 cm HO; 95% CI 4.98-11.91), and the presence of inspiratory muscle weakness did not change this result.
Isolated IMT improved inspiratory muscle strength, functional capacity, and pulmonary function, without changing dyspnea and quality of life. Associated IMT only increased inspiratory muscle strength. These results indicate that isolated IMT can be considered as an adjuvant intervention in patients with COPD.
吸气肌训练(IMT)对 COPD 患者的益处已在文献中得到证实,但它的单独效果或与其他干预措施的联合效果、最佳训练方法以及哪种类型的患者受益最大尚不清楚。我们旨在评估 IMT 对 COPD 患者呼吸肌力量、肺功能、呼吸困难、功能能力和生活质量的影响,同时考虑 IMT 的单独应用或与其他干预措施的联合应用、吸气肌无力的存在、训练负荷和干预时间。
我们于 2018 年 6 月检索了 MEDLINE、EMBASE、PEDro、Cochrane 中心和 LILACS 数据库。我们还对数据库检索中发现的并纳入本分析的研究的参考文献进行了手工检索。我们纳入了评估上述结局并将 IMT 与对照组、安慰剂或其他干预措施进行比较的随机对照试验,这些试验在 COPD 患者中单独或联合其他干预措施评估 IMT。我们使用 GRADE 方法评估证据质量。
在 1230 项检索结果中,有 48 项符合纳入标准(共纳入 1996 例患者)。单独应用 IMT 可增加 P(10.64 cm HO,95%CI 7.61-13.66)、6 分钟步行试验中的步行距离(34.28 m;95%CI 29.43-39.14)和 FEV(0.08,95%CI 0.02-0.13)。然而,呼吸困难和生活质量并未得到改善。吸气肌无力的存在并未改变结果;较高的负荷(60-80%的 P)可更大程度地改善这些结局,较短的干预时间(4 周)可改善 P,但需要更长的干预时间(6-8 周)才能改善功能能力。与其他干预措施联合应用 IMT 仅增加了 P(8.44 cm HO;95%CI 4.98-11.91),且吸气肌无力的存在并未改变这一结果。
单独应用 IMT 可改善吸气肌力量、功能能力和肺功能,而不改变呼吸困难和生活质量。联合应用 IMT 仅增加吸气肌力量。这些结果表明,单独应用 IMT 可作为 COPD 患者的辅助治疗措施。